Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of AJU-A53 (Dapagliflozin/Linagliptin/Metformin) in Healthy Adults
NCT07034781Phase 1Not yet recruiting
- Sponsor
- AJU PHARM Co., Ltd.
- Start
- Aug 2025
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dapagliflozin + linagliptin + metformin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by AJU PHARM Co., Ltd. Primary endpoints: Maximum Observed Plasma Concentration (Cmax) of Dapagliflozin, Area Under the Plasma Concentration-Time Curve (AUCt) of Dapagliflozin and 4 more. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
dapagliflozin + linagliptin + metformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07034781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07034781.